Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.43 |
| ▸ | NRAS | P01111 | 4/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30156407 | 1.00 | FLT3 (0.43) | FLT3NRASIRAK4TGFBR1MTOR | |
| SCHEMBL23392192 | 0.91 | IRAK4 (0.43) | FLT3IRAK4PIM1PIM2 | |
| SCHEMBL30156322 | 0.91 | IRAK4 (0.43) | FLT3IRAK4PIM1PIM2 | |
| SCHEMBL23391953 | 0.88 | TGFBR1 (0.38) | FLT3NRASTGFBR1MTORCYP2D6 | |
| SCHEMBL23392167 | 0.81 | MET (0.46) | FLT3NRASIRAK4TGFBR1MTOR | |
| SCHEMBL30156389 | 0.80 | TGFBR1 (0.40) | TGFBR1CYP2D6 | |
| SCHEMBL25084803 | 0.80 | TGFBR1 (0.40) | TGFBR1CYP2D6 | |
| SCHEMBL30156350 | 0.79 | TGFBR1 (0.36) | IRAK4TGFBR1MTORCYP2D6TGFBR2 | |
| SCHEMBL25084503 | 0.79 | MET (0.44) | IRAK4TGFBR1MTORCYP2D6PIM1 | |
| SCHEMBL30156413 | 0.79 | MET (0.44) | IRAK4TGFBR1MTORCYP2D6PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | FLT3 143/4885NRAS 1201/4885IRAK4 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.